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Abstract
Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative
component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent
inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed
the exploratory efficacy of MSC for MS.
Methods/design: This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II
clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at
either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of
MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical
and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis
(MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols
and sharing some key centralized procedures, including data collection and analyses.
Discussion: Results will provide patients and the scientific community with data on the safety and efficacy of MSC
for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model
to circumvent limitation of funds encountered by academic trials.
Trial registration: Andalusia: NCT01745783, registered on Dec 10, 2012.
Badalona: NCT02035514 EudraCT, 2010–024081–21. Registered on 2012.
Canada: ClinicalTrials.gov, NCT02239393. Registered on September 12, 2014.
Copenhagen: EudraCT, 2012–000518-13. Registered on June 21, 2012.
Italy: EudraCT, 2011–001295-19, and ClinicalTrials.gov, NCT01854957. Retrospectively registered on May 16, 2013.
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Background
The care of subjects with multiple sclerosis (MS) has
been revolutionized over the past 30 years, from no
treatment available until 1993, when interferon-beta 1b
was approved in the US, to 13 disease-modifying drugs
(DMD) approved in 2018 [1]. However, the evidence that
the vast majority of DMD only affect relapsing MS
makes the treatment scenario still unsatisfactory. MS is
an inflammatory disease of the central nervous system
(CNS) of autoimmune pathogenesis, characterized by
demyelination and axonal loss. Most patients first ex-
perience a relapsing disease course characterized by epi-
sodes of neurologic disability followed by complete or
partial recovery, which is believed to be driven by transi-
ent demyelination due to attack of immune cells coming
into the CNS from the periphery (relapsing-remitting
MS (RRMS)). RRMS is usually followed by a secondary
progressive phase whose clinical hallmark is a progres-
sive worsening of neurological status and establishment
of irreversible disability (secondary progressive phase of
disease (SPMS)). In about one out of five patients, the
clinical course is progressive from the onset (primary
progressive MS (PPMS)), though at least a quarter of
such patients continue to show evidence of inflamma-
tion by way of clinical attacks and newly forming MRI
lesions [2]. Immune mechanisms mainly driven by cells
of the innate immune system and compartmentalized re-
sponses within the CNS together with non-immune
mechanisms involving the CNS tissue, poorly targeted
by available DMDs, are believed to contribute to the
progressive phase [3, 4]. Prevention of cumulative dis-
ability and protection of the nervous tissue from the det-
rimental effects of inflammation are, therefore, the main
goals of MS treatment research and particularly of that
on stem cell-based treatments for MS.
Mesenchymal stem cells (MSC) are stromal [precur-
sor] cells residing in many tissues, including the bone
marrow (BM), where they support hematopoiesis. Treat-
ment with MSC improves the course of the preclinical
model of MS, experimental autoimmune encephalomy-
elitis (EAE), when administered at early stages. In EAE,
MSC have a profound anti-inflammatory and
immune-modulating effect [5–9], but they also exhibit
neuroprotective features and foster remyelination
endogenous neurogenesis with scarce evidence of differ-
entiation in neural cells [6, 10, 11].
In humans, MSC, either autologous or allogeneic, have
been used for more than 15 years in the treatment of
graft-versus-host disease, as well as for other indications,
showing a favorable safety profile [12, 13]. From these
considerations, the first trials with BM-derived MSC for
the treatment of MS were performed and published
starting from 2007 [14–18]. These trials involved a lim-
ited number of subjects, with moderate to severe disabil-
ity and active or progressive disease, treated with
autologous, BM-derived MSC administered either by
lumbar puncture (intrathecally) or intravenously (IV)
and at variable dosages, as reviewed in [19]. Due to the
low number of treated subjects, most trials were under-
powered for drawing conclusions on efficacy and re-
ported only data about the safety profile, which was
overall favorable; one study assessed efficacy in ten pa-
tients with SPMS and visual impairment, finding that
MSC treatment could improve some visual parameters
compared to the pre-treatment [17]. An exploratory
study with adipose tissue-derived MSC confirmed the
safety of the treatment [20].
Here we present the protocol of the MEsenchymal
StEm cells for Multiple Sclerosis (MESEMS) study, an
academic, phase I/II clinical trial aimed at assessing
safety as well as efficacy of a single intravenous (IV) dose
of autologous BM-derived MSC for MS.
Methods/design
The MESEMS trial
The general protocol of the trial was devised by a panel of
experts in stem cell research and/or in clinical research in
MS, and was based on a consensus published in 2010 [21].
The MESEMS trial is aimed to assess the safety and effi-
cacy of autologous, BM-derived MSC in a large cohort of
subjects with active MS through a double-blind, random-
ized, cross-over design. A dose of 1–2 × 106 MSC/kg body
weight and the IV route were chosen, as reviewed in [22].
Given the data from preclinical experience showing that
efficacy of MSC is achieved when cells are administered
before the chronic phase of disease is reached, patients
with relatively short disease duration (2 to 15 years since
onset) will be enrolled. Patients may be enrolled with
Uccelli et al. Trials          (2019) 20:263 Page 2 of 13
every form of disease (RRMS, SPMS, or PPMS), as long as
there is evidence the disease is active, as defined by inclu-
sion criteria specified below.
The MESEMS network
The major constraint to perform an academic
investigator-initiated phase 2 trial such as the MESEMS
trial is funding. Additionally, autologous cells are legally
classified in Europe as advanced therapy medicinal prod-
ucts (ATMPs) produced by good manufacturing practice
(GMP)-authorized cell factories governed by regulation
1394/2007/EC. For ATMPs, clinical studies are regulated
by each state through national guidelines requiring manu-
facturing authorization, resulting in regulatory and proced-
ural consequences, which makes harmonization difficult.
To overcome these issues, we followed a novel strategy—
a merging of partially independent clinical trials, following
the same protocol and sharing some key centralized proce-
dures, including data collection and analyses. Nine coun-
tries adhere to the MESEMS network, based in Italy
(Genova, Milano, and Verona), Canada (Ottawa and Win-
nipeg), Austria (Salzburg), Denmark (Copenhagen), France
(Toulouse), Iran (Tehran), Spain-Andalusia (Cordoba, Mal-
aga, and Sevilla), Spain-Catalonia (Badalona), Sweden
(Stockholm), and the United Kingdom (London).
Centralized MRI reading and analyses were performed at
the Medical Image Analysis Center (MIAC AG) in Basel,
Switzerland, an imaging Contract Research Organization
(CRO) specialized in phase II/III studies.
Trials performed within the MESEMS network share ob-
jectives and trial design, a central randomization procedure
through a web-portal, central collection of data through a
unique CRO based in Genova, Italy, and common funding
of some centralized procedures by non-profit organizations.
The trials have obtained independent authorization by na-
tional authorities (including amendments), have been regis-
tered to trial databases independently (either EudraCT or
Clinicaltrials.gov, or both), employ MSC isolated and ex-
panded by local cell factories, and may slightly differ in the
patient population, as detailed below.
A Memorandum of Understanding was signed by all
participating centers to guarantee compliance with the
trial rules and sharing of data for centralized analysis.
While the primary and secondary objectives are shared
among the single trials of the MESEMS network and are
going to be the object of a single publication, freedom is
given to all centers to perform independent, ancillary
studies to be published separately.
Financial support
Non-profit organizations and academic entities funded the
trial. Each national study was funded by national MS pa-
tients’ organizations and other non-profit agencies. Central-
ized activities were supported mainly by the Fondazione
Italiana Sclerosi Multipla (FISM) through a grant to sup-
port the activities of the CRO and some of the centralized
analysis of the MRIs at MIAC. Centralized activities were
also supported by grants of the European Committee for
Research in Multiple Sclerosis (ECTRIMS) and the Mul-
tiple Sclerosis International Foundation (MSIF).
MESEMS trial design
MESEMS is a double-blind, randomized, cross-over,
placebo-controlled trial lasting 56 weeks. The primary
endpoints are safety (measured as number and severity
of adverse events (AE)) of IV treatment with autologous
BM-derived MSC and efficacy on brain MRI within the
first 24 weeks after treatment. In detail, efficacy is de-
fined as the reduction in the number of contrast(gadoli-
nium-)-enhancing lesions (GEL) at 24 weeks in patients
who received MSC at week 0 compared to those who re-
ceived placebo. Secondary endpoints include efficacy at
48 weeks, comparison of early vs delayed treatment, and
clinical efficacy at 24 and 48 weeks (Tables 1 and 2).
The schedule of assessment is reported in Fig. 1 and a
schematic representation of the trial is depicted in Fig. 2. Pa-
tients enrolled in trials belonging to the MESEMS network,
after informed consent, undergo central randomization and
a BM aspirate (at week − 8). Cell factories GMP-approved by
national authorities expand the BM-derived MSC up to 1–
2 × 106/kg of subject body weight and, after the appropriate
quality checks, freeze one IV bag of MSC in infusion
medium and another IV bag containing infusion medium
(including cryoprotectant) only with no cells (i.e., placebo).
According to the central randomization code, each patient
receives one bag at baseline (week 0) and the other at week
24. Patients and investigators are blinded to the treatment.
For evaluation of safety, AE occurrence and severity are reg-
istered monthly since inclusion according to the CTC-AE
classification. For evaluation of efficacy, patients undergo a
contrast-enhanced brain MRI at baseline, followed by six fur-
ther MRI visits.
Table 1 Primary objectives of the MESEMS project
Aim Measures
Safety of IV therapy with
autologous BM-derived
MSC in RRMS, SPMS, and
PPMS subjects
Number and severity of AEs
within each treatment arm
Activity of autologous
BM-derived MSCs in MS subjects
Reduction compared to placebo
in the total number of
contrast-enhancing lesions (GEL)
at MRI acquired on conventional
MRI scans (minimum magnetic
field intensity 1.5 T) over 24 weeks
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Inclusion criteria
Patients included in the MESEMS trials must be aged 18–
50 years, have short disease duration (2–15 years since MS
onset, included), and moderate to severe disability (Ex-
panded Disability Status Scale 2.5 to 6.5, included). All tri-
als belonging to the MESEMS network allow inclusion of
MS patients with the relapsing-remitting (RR) form of dis-
ease, with recent relapse(s) and/or MRI activity, as de-
tailed in Table 3. Inclusion criteria for RRMS were
modified in the second version of the protocol in order to
define recent MRI activity not only as detection of one
GEL at MRI performed within the last 12months, but also
as detection of a new T2 lesion at MRI performed within
the last 12months compared to a previous MRI per-
formed within the last 12months. Most trials with one ex-
ception allow for the inclusion of patients with the
progressive form of disease. For the secondary progressive
(SP) form of disease, progression of disease in the past
year, in the presence of relapses or MRI activity, are re-
quired (Table 3), and for the primary progressive (PP)
form, progression of disease and MRI activity in the past
year are mandatory for inclusion (Table 3). Very recent
MRI activity (within the last 3months) is an additional re-
quirement for patients affected by all disease forms and
enrolled in the trial based in London in order to capture
highly active MS individuals.
Shared exclusion criteria are: disease form not fulfilling
inclusion criteria; any active or chronic infection, including
infection with HIV1/2 or chronic hepatitis B or hepatitis C;
any chronic or acute disease that could be not compatible
with the trial protocol as per clinician’s judgment; treatment
with any immunosuppressive therapy, including natalizu-
mab and fingolimod, within the 3months prior to
randomization; treatment with interferon-beta or glatira-
mer acetate within the 30 days prior to randomization;
treatment with alemtuzumab within the 12months prior to
randomization; treatment with rituximab/other anti-CD20
drug within the 6months prior to randomization; treat-
ment with corticosteroids within the 30 days prior to
randomization; relapse occurring during the 60 days prior
Table 2 Secondary objectives of the MESEMS project
Aim Measures
To compare the number of active MRI lesions in the placebo
vs active treatment periods in both groups
Number of GEL counted over weeks 28, 36, and 48 (cross-over re-treatment)
compared with the number of GEL counted over 4, 12, and 24 weeks
(placebo vs active treatment periods) within each group
To evaluate efficacy of MSC in reducing combined MRI activity
and volume of black holes (BH) in both treatment groups at
24 weeks
Combined unique MRI activity (number of new or enlarging T2w, or
enhancing or re-enhancing lesions) and volume of GEL over 4, 12, and
24 weeks compared between treatment groups. Volume of BH over 24
weeks compared between treatment groups
To compare combined MRI activity and volume of BH in the
placebo vs active treatment periods in both groups
Combined unique MRI activity and volume of GEL over weeks 28, 36, and
48 (cross-over re-treatment) compared with the same outcomes over 4,
12, and 24 weeks (placebo vs active treatment periods) within each group.
Volume of BH over week 48 (cross-over re-treatment) compared with the
same outcome over week 24 week (placebo vs active treatment periods)
within each group
To evaluate efficacy of MSC in reducing the volume of T2
lesions in both treatment groups at 24 weeks
Volume of T2w lesions over 24 weeks compared between treatment
groups
To compare the volume of T2 lesions in the placebo vs active
treatment periods in both groups
Volume of T2w lesions over week 48 (cross-over re-treatment) compared
with the same outcome over week 24 week (placebo vs active treatment
periods) within each group
To evaluate efficacy of MSC in reducing relapses at 24 weeks
and to compare the number of relapses in the placebo vs
active treatment periods in both groups
Number of relapses in MSC treatment group vs placebo group in the
first 24 weeks and after cross-over re-treatment in the two groups
(see below for definition of relapse)
To evaluate efficacy of MSC in reducing the time to sustained
progression of disability and increasing the number of progression-free
patients at 24 weeks and to compare the time to sustained
progression of disability and the proportion of progression-free
patients in the placebo vs active treatment periods in both groups*
Time to sustained progression of disability and proportion of
progression-free patients compared between treatment groups
during the first 24 weeks and after cross-over re-treatment in
the two groups
To evaluate efficacy of MSC in increasing the number of
progression-free patients at 24 weeks and to compare the
proportion of disease-free patients in the placebo vs active
treatment periods in both groups§
Proportion of disease-free patients compared between treatment
groups during the first 24 weeks and after cross-over re-treatment
in the two groups
To evaluate the efficacy of MSC treatment in clinical scores such
a Multiple Sclerosis Functional Composite (MSFC) score and
Symbol Digit Modalities Test (SDMT) score
Changes in MSFC and SDMT scores in the MSC treated group vs
placebo group during the first 24 weeks and after cross-over
re-treatment in the two groups
*Sustained progression of disease is defined as any 6-month sustained increase in EDSS: for baseline EDSS < 5.5, any 1-point EDSS increase; for baseline EDSS ≥
5.5, any 0.5-point EDSS increase
§Disease-free: patients without relapses, with no evidence of sustained progression of disability and new MRI activity
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to randomization (except for the trial based in London);
previous history of a malignancy other than basal cell car-
cinoma of the skin or carcinoma in situ that has been in re-
mission for more than one year (except for the trial based
in Copenhagen); severely limited life expectancy by another
co-morbid illness; history of previous diagnosis of myelo-
dysplasia or previous hematologic disease or current clinic-
ally relevant abnormalities of white blood cell counts;
pregnancy or risk of pregnancy (this includes patients that
are unwilling to practice active contraception during the
duration of the study); estimated glomerular filtration rate
< 60mL/min/1.73m2 or known renal failure or inability to
undergo MRI examination; inability to give written in-
formed consent in accordance with research ethics board
guidelines.
MSC preparation and culture
Upon arrival of BM at the cell factory within 12 h after
harvesting, MSC are expanded up to 1–2 × 106/kg of
body weight of the patient and frozen until usage; the
Andalusian cell factory follows a different procedure as
it freezes the BM cells upon arrival and expands the
MSC just before infusion without further freezing. Cell
culture media include alpha-minimum essential medium
(alpha-MEM) and low-glucose Dulbecco’s modified
Eagle medium (D-MEM). The growth supplement is hu-
man platelet lysate or fetal bovine serum (depending on
the protocol adopted by each cell factory). Cells are
grown in incubators at ambient oxygen level (21%).
MSC are harvested after a maximum number of two
passages. The final product is tested to exclude growth
of aerobic and anaerobic bacteria and Mycoplasma and
defined as adherent cells positive for CD73, CD90, and
CD105 and negative for CD14, CD34, and CD45, as de-
scribed later. Moreover, cytogenetic analysis is per-
formed to rule out an abnormal karyotype, as described
below.
Characteristics of the final MSC product
MSCs may be released from the laboratory for clinical
use if they fulfill the following criteria:
– CD105 expression ≥ 70%
– CD73 expression ≥ 70%
– CD90 expression ≥ 70%
– CD14 expression ≤ 10%
– CD45 expression ≤ 10%
– CD34 expression ≤ 10%
– Viability ≥ 80% at the time of freezing and in an
aliquot thawed 2–3 weeks after freezing
– Detection of ≥ 70% expression of CD73, CD90, and
CD105 in an aliquot thawed 2–3 weeks after
freezing
– Lack of colony forming capacity in methylcellulose
– Lack of abnormal karyotype detected in at least 20
metaphases analyzed (unless an insufficient number
of metaphases is obtained due to low cell growth as
evidenced by the mitotic index)
Fig. 1 Schedule of enrolment, interventions, and assessments of the MESEMS trial. *Optional studies as per sites desire; §MRI at week 0 and week
24 must be performed before the IV treatment with MSC or placebo
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Statistical analysis
Sample size
To evaluate the safety of MSC infusion, the number,
timeframe of occurrence, and severity of AE will be re-
corded in MSC and placebo treatment groups. For the
evaluation of efficacy, a sample size of 160 patients was
estimated to give 80% power at a significance level of 5%
to detect a decrease of 50% in the number of GEL
counted during the 6-month duration of treatment. This
number was estimated assuming that the average num-
ber of total GEL on three MRI scans (performed at
weeks 4, 12, and 24) will be 7.4 (SD = 11.4), that is, half
of the total number of GEL counted over six monthly
MRIs in the phase II study of the oral drug fingolimod
for MS [23]. Given a possible drop-out rate of 15% (N =
24), the total number of patients to enroll will be 185.
Data analysis
For the primary outcome, comparisons of the incidence
and severity of adverse events between treatment groups
will be carried out by the chi-square test.
For the co-primary outcome, the total number of GEL
lesions at MRI at weeks 4, 12, and 24 will be compared
between treatment groups using a negative binomial
(NB) regression analysis, adjusting for the number of
GEL at baseline.
For secondary outcomes, the total number of GEL at
MRI at weeks 4, 12, and 24 in each treatment group will be
compared with the number of GEL lesions at MRI at weeks
28, 36, and 48 following the infusion using a
non-parametric statistic for paired data. The dependence
on time of the total number of GEL at MRI will be analyzed
in the group originally randomized to active treatment
Treatment
Informed
consent
Randomizatio
Treatment
MSC Harvest and Processing
MSC cryopreserved
Arm #1
Early Tx
Arm #2
Delayed 
MSC Infusion Sham MSC Infusion
MSC Infusion Sham MSC infusion 
0
24
24
-
48
- 8
Follow up
NO YES
Time
(week)
0
-
24
Follow up
Fig. 2 Study design and patient flow in the MESEMS trial
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using a mixed effect generalized model with NB errors. The
total number of new or enlarging T2w lesions at weeks 4,
12, and 24 post-treatment will be contrasted in the two
groups using a NB regression analysis with treatment group
and baseline number of GEL lesions as covariate. MRI le-
sion volumes will be log-transformed and compared by
ANOVA models between groups. The total number of
combined unique lesions, at week 4, 12 and 24 weeks
post-treatment will be contrasted in the two groups using a
NB regression analysis with treatment group and baseline
number of GEL lesions as covariate. MRI lesion volumes
will be log-transformed and compared by ANOVA models
between groups. The combined unique MRI activity, num-
ber of new T2w lesions, volume of GEL over weeks 28, 36,
and 48, the T2w and the BH volume changes between
weeks 24 and 48 (cross-over re-treatment) will be com-
pared with combined unique MRI activity, number of new
T2w lesions, volume of GEL over 4, 12, and 24weeks, T2w
and BH volume changes between baseline and week 24
(placebo vs active treatment periods) using a
non-parametric statistic for paired data. The number of re-
lapses in the MSC treatment group vs the placebo group
will be compared using a NB regression analysis. Time to
sustained progression of disability (RRMS group) will be
analyzed with a Cox proportional-hazards model. The pro-
portion of progression-free patients in the two groups will
be compared by using the chi-square test (RRMS patients).
Mean changes in Multiple Sclerosis Functional Composite
(MSFC) score and in SDMT score in MSC treatment group
vs placebo group compared to baseline will be analyzed
with a one-way ANOVA test.
Assessment of inter-center differences
Stringent phenotypic criteria have been adopted for
MSC cell release. Moreover, we adopted an electronic
case record form (eCRF) containing very detailed tem-
plates related to MSC production. However, the primary
analysis will not be adjusted for center effect due to the
small number of patients expected to be enrolled per
center. As such, no subgroup analysis has been planned
per study protocol. Regarding the possible variability in
the number of infused cells, the stem cell relevant tem-
plates in the eCRF contain information on MSC viability
in the final cell product; therefore, an exploratory ana-
lysis will be run to correlate the total number of infused
MSCs—a continuous variable allowing such type of ana-
lysis—to efficacy outcome. However, due to the small ex-
pected sample size, this analysis will not be powered to
detect significant treatment effect differences and will
only be used to generate hypotheses.
Treatment of relapses
Any patient complaining of a new neurological symptom
suggestive of relapse should be referred to the examining
neurologist for EDSS assessment. Investigators may treat
relapses with intravenous methylprendnisolone, 1000
mg, for 3 to 5 consecutive days.
Prohibited concomitant medications
The treatment with immunmodulatory or immunosup-
pressive drugs for MS during the trial is prohibited.
Centralized study procedures
Centralized randomization and data entry
Once all the eligibility criteria have been checked, and
patients have signed the informed consent, they will be
randomized through the randomization website (https://
trials.actide.com/mesems/live/public/en/users/login) ad-
ministered by the CRO “Latis”, which provides the in-
vestigators with access credentials.
Throughout the study, investigators are required to fill
an eCRF, administered by the CRO and accessible with
personal credential from the website https://trials.actide.
com/mesems/live/public/en/users/login.
Centralized reading of the MRI
Scanners for MRI must have a minimum magnetic field
intensity of 1.5 T. In order to ensure optimal MRI data
quality, a “dummy run” scan must be uploaded by each
center through the MIAC web-portal and, upon revision,
quality must be accepted before patient’s enrollment. Pa-
tients undergo seven MRI visits at defined timepoints, as
detailed before and in the schedule of assessment; MRI
scans scheduled for week 0 and week 24 must be per-
formed before the treatment. MRI data are uploaded
electronically to the MIAC website and analyzed cen-
trally in a blinded fashion.
On-site procedures
Bone marrow harvest
BM will be harvested at randomization visit according to
Good Clinical Practice guidelines. Briefly, a total of 10 to
100ml of BM aspirate will be collected after performing
multiple small incisions and perforations from the
posterior-superior iliac spine under local anesthesia. Anti-
coagulant will be added to the aspiration syringes and to
the bag where the bone marrow will be collected prior to
delivery to the cell factory under computer-controlled
temperature (not at all sites).
Administration of the investigational product
At week 0 a single infusion of either ex vivo expanded
autologous MSC or placebo will be administered IV, ac-
cording to randomization, after premedication with nor-
mal saline and an anti-histamine drug to prevent
infusion reactions to AB plasma or to dimethyl sulfox-
ide, which are in the MSC bag as well as the placebo bag
(concomitant treatment with steroids is not allowed at
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time of infusion). Subjects will be monitored for up to 2
h following administration. At week 24, another infusion
will be performed for cross-over re-treatment: at week
24, treatments will be reversed compared to week 0 (i.e.,
patients who received initial MSCs will receive suspen-
sion media and vice versa) and will be administered fol-
lowing the same protocol as described for week 0.
Follow-up visits
At scheduled visits, vital signs and AE will be recorded.
Other procedures will be performed according to the
study schedule as depicted in Table 1. Investigators will
be divided into “treating neurologist”, the physician re-
sponsible for the patient care, AE recording and treat-
ment administration, and “examining neurologist”, the
physician performing the neurological evaluation.
SPIRIT checkist for this trial is reported in Additional
file 1.
Monitoring of AE
All AE
All AEs that occur between the first study-related proced-
ure and 6 months post-administration of the last dose of
study drug (or after this date if the investigator feels the
event is related to the study drug) must be recorded by in-
vestigators in the eCRF. Those meeting the definition of a
serious adverse event (SAE) related or not to the study
treatment must be reported within 24 h to the CRO.
Severity
Severity for each AE, including any laboratory abnormal-
ity, will be determined by using the National Cancer In-
stitute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE, version 4.0) as a guideline,
wherever possible. The criteria are available online at
https://ctep.cancer.gov/protocoldevelopment/electronic_
applications/ctc.htm#ctc_40.
In those cases where the CTCAE criteria do not apply,
severity should be defined according to the following
criteria:
 Mild (grade 1): Awareness of signs or symptoms,
but easily tolerated
 Moderate (grade 2): Discomfort enough to cause
interference with normal daily activities
 Severe (grade 3): Inability to perform normal daily
activities
 Life threatening (grade 4): Immediate risk of death
from the reaction as it occurred
Causality
Relationship to study drug administration will be deter-
mined as follows:
 None: No relationship between the experience and
the administration of the study drug; related to
other etiologies such as concomitant medications or
patient’s clinical state.
 Unlikely: The current state of knowledge indicates
that the relationship is unlikely.
 Possible: A reaction that follows a plausible temporal
sequence from administration of the study drug and
follows a known response pattern to the suspected
study drug. The reaction might also have been
produced by the patient’s clinical state or other
modes of therapy administered to the patient.
 Probable: A reaction that follows a plausible
temporal sequence from administration of the study
drug and follows a known response pattern to the
suspected study drug. The reaction cannot be
reasonably explained by the known characteristics of
the patient’s clinical state or other modes of therapy
administered to the patient.
 Definite: An AE which is listed as a possible adverse
reaction and cannot be reasonably explained by an
alternative explanation, e.g., concomitant drug(s),
concomitant disease(s).
Serious adverse events
The enrolling sites will be responsible for pharmacovigi-
lance. Events defined as serious must be reported by the
centers according to Good Clinical Practice and the local
protocol.
The following attributes must be assigned when
reporting:
 Detailed description of the event
 Date of onset and date of resolution
 Severity of the event (see “Severity” section for
details)
 Assessment of relatedness to study drugs (see
“Causality” section for definitions) and action taken
 Other suspect drugs/devices
 Outcome
All SAEs will be followed up until resolution or study
end. The investigator will be asked to provide interim and
follow-up reports, as necessary, if the SAE has not resolved
at the time of initial report. All deaths (CTCAE grade 5) oc-
curring during the study must be reported as an SAE.
Monitoring
Patient registration, randomization and data entry of all
clinical, laboratory, and MRI data will be performed via an
eCRF accessible through the web by authorized re-
searchers and administered by the CRO. The principal in-
vestigator of every trial will be responsible for ensuring
that medical and paramedical staff are allocated to provide
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adequate source documentation and to fill the required
items in the eCRF. The eCRF should be submitted within
2 weeks of completion of the study treatment and each
study follow-up visit. All study-related eCRFs will be
stored for 5 years in the archives of each center.
Study management, monitoring, and database manage-
ment will be the responsibility of the CRO–Latis (Ge-
nova, Italy), whereas design and biostatistical analysis
will be guaranteed by the Biostatistics Unit, Department
of Health Sciences of the University of Genoa (Italy).
An International Trial Steering Committee (ISC) was
appointed to provide guidance to the trial. Members of
the ISC are listed in Additional file 2. Furthermore, four
independent researchers, experts in the field of adult
stem cells, clinical trials in MS, neuroimmunology, and
neuroradiology, respectively, who oversee monitoring of
the safety of the treatment, compose the Independent
Data Safety Monitoring Committee (IDSMC). Members
of the IDSMC are listed in Additional file 2.
The ISC comprises the principal investigator of each
national trial, as well as other expert representatives es-
sential for the conduct of the international collaborative
trial, including in statistics, MRI, and cell production.
The ISC will be responsible for the actual conduct of the
trial and will decide on the distribution of funds received
from the international funding bodies. It will meet once
or twice yearly to recapitulate the progress of the trial,
discuss issues that may arise about study procedures,
and make decisions based on the recommendations of
the IDSMC. Decisions will be implemented upon major-
ity agreement of members.
Members of the IDSMC have accepted to serve as
members of the IDSMC under a confidentiality agree-
ment. Through quarterly meetings, they will review
safety and toxicity reports (tables and listings) they will
receive directly from the CRO and give their recommen-
dations thereof to ensure subjects’ safety throughout the
trial. In addition, the IDSMC will be requested by the
CRO to give their recommendations in individual cases
where an unexpected SAE clearly related to the treat-
ment has occurred. Unblinding is restricted to emer-
gency situations. It should be used only under
circumstances where the knowledge of the treatment is
necessary for the proper handling of the patient. In this
case a “Request of unblinding form” must be completed
by the investigator and sent by fax/email to the CRO,
which will communicate by fax/email the treatment to
the Investigators in a timely manner.
Patient confidentiality
In order to maintain patient privacy, all data capture re-
cords, study drug accountability records, and study re-
ports and communications will identify the patient by
initials and the assigned patient number. The investigator
will grant the study monitor(s) and auditor(s) access to
the patient’s original medical records for verification of
data gathered on the data capture records and to audit the
data collection process. The patient’s confidentiality will
be maintained and will not be made publicly available to
the extent permitted by the applicable laws and
regulations.
Premature closure of the study
This study may be prematurely terminated if, in the
opinion of the investigator, there is sufficient reasonable
cause. The terminating party will provide written notifi-
cation documenting the reason for study termination to
the investigator. Circumstances that may warrant ter-
mination include, but are not limited to:
 Treatment-related mortality: in case of one fatal
accident 24 h after treatment, the IDSMC will
evaluate the case and decide whether the trial
should be stopped. The trial is stopped after the
second fatal event 24 h after treatment.
 Determination of unexpected, significant, or
unacceptable risk to patients.
 Failure to enter patients at an acceptable rate.
 Insufficient adherence to protocol requirements.
 Insufficient complete and/or valuable data.
 Protocol violation.
 Administrative decision.
 New data able to influence the willingness of the
investigators to pursue the study.
Use of information and publication
The results of the study will be reported in a Clinical
Study Report generated by the sponsors and will contain
all data from all investigational sites. Any work created
in connection with performance of the study and con-
tained in the data that can benefit from copyright pro-
tection (except any publication by the investigator as
provided for below) shall be the property of the sponsor
as author and owner of copyright in such work. The par-
ticipating centers will recognize the integrity of a double
center study by not publishing data derived from the in-
dividual site until the combined results from the com-
pleted study have been published in full. Authorship of
publications resulting from this study will be based on
generally accepted criteria for major medical journals.
Discussion and potential impact
The MESEMS trial will provide patients and scientific
communities with the answers to two key questions
about MSC-based treatment of MS: 1) whether autolo-
gous, BM-derived MSC are safe in the MS population;
and 2) whether autologous, BM-derived MSC are effica-
cious in decreasing MS activity.
Uccelli et al. Trials          (2019) 20:263 Page 10 of 13
Stem cell-based therapies are often advertised to the
public as a panacea for every disease with a degenerative
component, for their supposed capability to regenerate
diseased tissues through engraftment paracrine effects
and/or transdifferentiation, despite the lack of scientific
evidence and clinical proof of concept (http://www.nature.
com/news/italian-stem-cell-trial-based-on-flawed-data-1.
13329) [24]. Preclinical evidence shows that MSC are in-
deed effective in an animal model of MS, but their mech-
anism of action appears to involve a combination of
modulation of the peripheral immune system and promot-
ing tissue protection. The small numbers of patients in-
volved in the published trials with MSC for MS do not
allow us to draw conclusions on whether preclinical find-
ings are applicable to human beings.
Based on the sample size calculation, the MESEMS
trial design should overcome such methodological issues
by enrolling enough patients for analyzing efficacy on
MRI metrics. MRI activity is a recognized marker for
clinical activity (i.e., relapses) in MS and is the primary
efficacy outcome in most phase II clinical trials with
novel drugs for relapsing MS [25].
Importantly, the MESEMS trial is not powered to give
conclusive answers on whether MSC are effective in pro-
moting tissue protection, i.e., in preventing disability,
but rather seeks as a phase 2 trial to assess exploratory
efficacy. Accordingly, confirmatory efficacy results need
to be obtained with a larger subject study population
and a longer follow-up period, which is beyond the
scope of this collaborative phase 2 effort. However, ana-
lysis of secondary endpoints will gather some prelimin-
ary information which could be possibly utilized to
design a future, confirmatory phase III trial.
The trial has the peculiarity of being composed of sev-
eral national trials, partially independent but sharing the
protocol and some key procedures, such as central
randomization and data collection. Such an innovative
trial design, created in order to overcome financial and
technical obstacles that would have otherwise prevented
us from carrying out the study, has obtained support
and endorsement by eminent charities and funding bod-
ies, such as FISM, ECTRIMS, and the MSIF (“We appre-
ciate the challenges involved in bringing together a
number of smaller datasets and applying a common ana-
lysis plan to them but believe this to be an important
step in getting the most from the data” – letter of en-
dorsement to the study from Peer Baneke, Chief Execu-
tive and Alan Thompson, Chairman, IMSB of MSIF on
February 23, 2012).
Such a collaborative group could constitute an ex-
ample for other research groups aiming to assess the ef-
ficacy of stem cell-based treatments for other neurologic
diseases such as, among others, Parkinson’s disease,
amyotrophic lateral sclerosis, or spinal cord injury,
where clinical trials with MSC have been performed so
far in limited numbers of patients [19].
Additional files
Additional file 1: SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 256 kb)
Additional file 2: Supplementary materials. (DOCX 27 kb)
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